Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver.

Authors
  • Wallace, Marsha D
  • Pfefferle, Adam D
  • Shen, Lishuang
  • McNairn, Adrian J
  • Cerami, Ethan G
  • Fallon, Barbara L
  • Rinaldi, Vera D
  • Southard, Teresa L
  • Perou, Charles M
  • Schimenti, John C
Type
Published Article
Journal
Genetics
Publisher
The Genetics Society of America
Publication Date
Oct 01, 2012
Volume
192
Issue
2
Pages
385–396
Identifiers
DOI: 10.1534/genetics.112.142802
PMID: 22851646
Source
Medline
License
Unknown

Abstract

Identifying genomic alterations driving breast cancer is complicated by tumor diversity and genetic heterogeneity. Relevant mouse models are powerful for untangling this problem because such heterogeneity can be controlled. Inbred Chaos3 mice exhibit high levels of genomic instability leading to mammary tumors that have tumor gene expression profiles closely resembling mature human mammary luminal cell signatures. We genomically characterized mammary adenocarcinomas from these mice to identify cancer-causing genomic events that overlap common alterations in human breast cancer. Chaos3 tumors underwent recurrent copy number alterations (CNAs), particularly deletion of the RAS inhibitor Neurofibromin 1 (Nf1) in nearly all cases. These overlap with human CNAs including NF1, which is deleted or mutated in 27.7% of all breast carcinomas. Chaos3 mammary tumor cells exhibit RAS hyperactivation and increased sensitivity to RAS pathway inhibitors. These results indicate that spontaneous NF1 loss can drive breast cancer. This should be informative for treatment of the significant fraction of patients whose tumors bear NF1 mutations.

Report this publication

Statistics

Seen <100 times